Volume 35, No 4, Apr 2025

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 35 Issue 4, April 2025: 235-236

RESEARCH HIGHLIGHTS

A GSDMD agonist boosts specific antitumor immunity

Yingying Zhang¹ , Jiahuai Han^1,2,3,*

¹State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, China
²Research Unit of Cellular Stress of Chinese Academy of Medical Science, Xiang’an Hospital of Xiamen University, Cancer Research Center of Xiamen University, School of Medicine, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, Fujian, China
³Laboratory Animal Center, Xiamen University, Xiamen, Fujian, China
Correspondence: Jiahuai Han(jhan@xmu.edu.cn)

The beneficial role of gasdermin activation and pyroptosis induction in antitumor immunity has been implicated by several studies; however, the question of how to specifically and efficiently activate cancer cell death while minimizing toxicity to host cells remains unsolved. In a recent paper published in Cell, Wu and Lieberman groups identified a GSDMD agonist that can induce low-level pyroptosis in cancer cells but not in host cells, offering potential applications in cancer vaccine development and therapy in combination with checkpoint blockade.

https://doi.org/10.1038/s41422-024-01051-x

FULL TEXT | PDF

Browse 201